(TNDM) Tandem Diabetes Care - Ratings and Ratios
Insulin Pumps, Cartridges, Infusion Sets, Software, Mobile App
TNDM EPS (Earnings per Share)
TNDM Revenue
Description: TNDM Tandem Diabetes Care
Tandem Diabetes Care Inc (NASDAQ:TNDM) is a US-based company operating in the Health Care Equipment sub-industry. The companys stock has been under significant pressure, with its current price hovering around $10.84, far below its 52-week high of $45.71.
From a fundamental analysis perspective, Tandem Diabetes Cares Market Cap stands at approximately $758.81 million. The companys Return on Equity (RoE) is deeply negative at -104.11%, indicating substantial losses. The absence of a Forward P/E ratio suggests that the company is not expected to generate positive earnings in the near future.
Key economic drivers for Tandem Diabetes Care include the growing demand for diabetes management solutions, competition in the diabetes care market, and the companys ability to innovate and bring new products to market. KPIs to watch include revenue growth, gross margin expansion, and the companys cash burn rate, which will be crucial in determining its ability to achieve profitability.
The companys quarterly Tax Provision is an important metric to monitor, as it can provide insights into Tandem Diabetes Cares tax obligations and potential cash outflows. A thorough analysis of this metric, in conjunction with other financial statements, can help investors better understand the companys financial health and make more informed investment decisions.
To evaluate Tandem Diabetes Cares investment potential, it is essential to assess its product pipeline, market share, and competitive positioning. Additionally, investors should monitor the companys progress in reducing its losses and achieving profitability, as well as its ability to manage its cash resources effectively.
TNDM Stock Overview
| Market Cap in USD | 864m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2013-11-14 |
TNDM Stock Ratings
| Growth Rating | -88.8% |
| Fundamental | 34.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -75.7% |
| Analyst Rating | 3.71 of 5 |
TNDM Dividends
Currently no dividends paidTNDM Growth Ratios
| Growth Correlation 3m | -83.5% |
| Growth Correlation 12m | -87.8% |
| Growth Correlation 5y | -83.5% |
| CAGR 5y | -40.45% |
| CAGR/Max DD 3y | -0.49 |
| CAGR/Mean DD 3y | -0.93 |
| Sharpe Ratio 12m | -0.71 |
| Alpha | -86.39 |
| Beta | 0.709 |
| Volatility | 64.28% |
| Current Volume | 2114.7k |
| Average Volume 20d | 1870.5k |
| Stop Loss | 11.5 (-6.3%) |
| Signal | -0.77 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-205.5m TTM) > 0 and > 6% of Revenue (6% = 67.3m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 9.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.39% (prev 61.91%; Δ -29.51pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 9.72m > Net Income -205.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (67.0m) change vs 12m ago 3.16% (target <= -2.0% for YES) |
| Gross Margin 46.95% (prev 49.06%; Δ -2.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 123.7% (prev 84.91%; Δ 38.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -23.98 (EBITDA TTM -177.7m / Interest Expense TTM 8.12m) >= 6 (WARN >= 3) |
Altman Z'' -5.04
| (A) 0.41 = (Total Current Assets 614.8m - Total Current Liabilities 251.7m) / Total Assets 875.7m |
| (B) -1.41 = Retained Earnings (Balance) -1.23b / Total Assets 875.7m |
| warn (B) unusual magnitude: -1.41 — check mapping/units |
| (C) -0.21 = EBIT TTM -194.8m / Avg Total Assets 906.6m |
| (D) -1.65 = Book Value of Equity -1.23b / Total Liabilities 742.5m |
| Total Rating: -5.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.09
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 0.57% = 0.28 |
| 3. FCF Margin 0.45% = 0.11 |
| 4. Debt/Equity 2.47 = 0.05 |
| 5. Debt/Ebitda -1.85 = -2.50 |
| 6. ROIC - WACC -42.74% = -12.50 |
| 7. RoE -104.1% = -2.50 |
| 8. Rev. Trend 57.84% = 2.89 |
| 9. Rev. CAGR 6.09% = 0.76 |
| 10. EPS Trend -0.26% = -0.01 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of TNDM shares?
Over the past week, the price has changed by -1.84%, over one month by +15.10%, over three months by -38.77% and over the past year by -71.26%.
Is Tandem Diabetes Care a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TNDM is around 6.79 USD . This means that TNDM is currently overvalued and has a potential downside of -44.66%.
Is TNDM a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 10
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TNDM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.6 | 84.4% |
| Analysts Target Price | 22.6 | 84.4% |
| ValueRay Target Price | 7.4 | -39.4% |
Last update: 2025-09-04 04:49
TNDM Fundamental Data Overview
CCE Cash And Equivalents = 315.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 1111.1111
P/S = 0.8621
P/B = 6.479
Beta = 1.472
Revenue TTM = 1.12b USD
EBIT TTM = -194.8m USD
EBITDA TTM = -177.7m USD
Long Term Debt = 309.1m USD (from longTermDebt, last quarter)
Short Term Debt = 19.9m USD (from shortTermDebt, last quarter)
Debt = 329.0m USD (Calculated: Short Term 19.9m + Long Term 309.1m)
Net Debt = 384.9m USD (from netDebt column, last quarter)
Enterprise Value = 877.2m USD (863.5m + Debt 329.0m - CCE 315.4m)
Interest Coverage Ratio = -23.98 (Ebit TTM -194.8m / Interest Expense TTM 8.12m)
FCF Yield = 0.57% (FCF TTM 4.99m / Enterprise Value 877.2m)
FCF Margin = 0.45% (FCF TTM 4.99m / Revenue TTM 1.12b)
Net Margin = -18.33% (Net Income TTM -205.5m / Revenue TTM 1.12b)
Gross Margin = 46.95% ((Revenue TTM 1.12b - Cost of Revenue TTM 594.7m) / Revenue TTM)
Tobins Q-Ratio = -0.71 (set to none) (Enterprise Value 877.2m / Book Value Of Equity -1.23b)
Interest Expense / Debt = 0.77% (Interest Expense 2.54m / Debt 329.0m)
Taxrate = 21.0% (US default)
NOPAT = -194.8m (EBIT -194.8m, no tax applied on loss)
Current Ratio = 2.44 (Total Current Assets 614.8m / Total Current Liabilities 251.7m)
Debt / Equity = 2.47 (Debt 329.0m / last Quarter total Stockholder Equity 133.3m)
Debt / EBITDA = -1.85 (Net Debt 384.9m / EBITDA -177.7m)
Debt / FCF = 65.89 (Debt 329.0m / FCF TTM 4.99m)
Total Stockholder Equity = 197.3m (last 4 quarters mean)
RoA = -23.46% (Net Income -205.5m, Total Assets 875.7m )
RoE = -104.1% (Net Income TTM -205.5m / Total Stockholder Equity 197.3m)
RoCE = -38.46% (Ebit -194.8m / (Equity 197.3m + L.T.Debt 309.1m))
RoIC = -36.32% (NOPAT -194.8m / Invested Capital 536.3m)
WACC = 6.42% (E(863.5m)/V(1.19b) * Re(8.63%)) + (D(329.0m)/V(1.19b) * Rd(0.77%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 87.88 | Cagr: 0.39%
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 67.85% ; FCFE base≈4.99m ; Y1≈3.28m ; Y5≈1.50m
Fair Price DCF = 0.40 (DCF Value 26.7m / Shares Outstanding 67.6m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 57.84 | Revenue CAGR: 6.09%
Rev Growth-of-Growth: 19.26
EPS Correlation: -0.26 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -23.79
Additional Sources for TNDM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle